ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, imatinib was approved for the treatment of chronic myelogenous leukemia (CML) caused by BCR-ABL over expression [5], c-KIT-positive metastatic tumor and gastrointestinal stromal tumor [6].